HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights

New Leadership Appointments; Positive Clinical and Regulatory Reports for the Lead Product Candidate, HB-200 (eseba-vec); On track to initiate the Phase 2/3 “AVALON-1” study with eseba-vec in Q4 2024

Read more at globenewswire.com